ALKS-2680 is a small molecule commercialized by Alkermes, with a leading Phase II program in Type 1 Narcolepsy (Narcolepsy with Cataplexy);Type 2 Narcolepsy (Narcolepsy without Cataplexy). According to Globaldata, it is involved in 5 clinical trials, of which 1 was completed, 3 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of ALKS-2680’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for ALKS-2680 is expected to reach an annual total of $30 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
ALKS-2680 Overview
It was under development for the treatment of disorders associated with excessive daytime sleepiness.
Alkermes Overview
Alkermes is a biopharmaceutical company that focuses on the research, development, and commercialization of drugs for the treatment of cancer, neurodegenerative and central nervous system (CNS) diseases. The company’s proprietary products include Aristada and Aristada Initio an extended-release intramuscular injectable suspension for the treatment of schizophrenia; and Vivitrol, a once-monthly, non-addictive, injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence. It grants licenses under its proprietary technologies to enable third parties to develop, commercialize, and manufacture products. Alkermes sells its products primarily to pharmaceutical wholesalers, treatment providers, specialty distributors and pharmacies. The company has global operations. Alkermes is headquartered in Dublin, Ireland.
The company reported revenues of (US Dollars) US$1,663.4 million for the fiscal year ended December 2023 (FY2023), an increase of 49.6% over FY2022. The operating profit of the company was US$414.1 million in FY2023, compared to an operating loss of US$6.1 million in FY2022. The net profit of the company was US$355.8 million in FY2023, compared to a net loss of US$158.3 million in FY2022.
The company reported revenues of US$399.1 million for the second quarter ended June 2024, an increase of 13.9% over the previous quarter.
For a complete picture of ALKS-2680’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.